2 reports

  • PIPELINE BY GERON CORP, H2 2018

WE ARE PROUD TO HAVE TREATED OUR FIRST PATIENT WITH A POWERFUL COMBINATION OF INOVIO' S T CELL-GENERATING IMMUNOTHERAPY INO-## WITH REGENERON' S PD-## CHECKPOINT INHIBITOR THIS WEEK.

  • Cancer
  • Immunotherapy
  • Lung Cancer
  • Therapy
  • Geron Corporation
  • ASTVAC-2 - DRUG PROFILE

Patients will be assigned randomly on a blinded basis on a ##:## ratio to one of two dosing arms - ##. ## mg/ kg every three weeks or ##. ## mg/ kg every three weeks.

  • Antiviral
  • Immunotherapy
  • Therapy
  • Vaccine
  • Geron Corporation